Alex M. DiNello
President and Chief Executive Officer
Alex DiNello brings over 30 years of experience in the medical industry, including 25 years of experience focusing on the spine and pain markets. He has extensive product, clinical development, and commercialization experience in the space and has brought over 60 products to market across the globe. Prior to joining Sollis Therapeutics, DiNello served as Chief Technology Officer, COO, and CEO respectively for Relievant Medsystems, Inc. achieving FDA clearance and commercialization for the Intracept System, a novel therapy for the treatment of chronic low back pain. Prior to Relievant, he served as vice president and general manager for Medtronic Kyphon where he was accountable for $400 million of worldwide business. He was promoted to the general manager position at Medtronic Kyphon from the position of vice president of research and development. Previous to that, he was vice president of research and development for Abbott Spine. He has served in various other positions in the medical device industry, including serving as vice president of strategic development and research and development at DePuy Spine, Johnson & Johnson.
Mr. DiNello holds a B.S. in Mechanical Engineering from University of California at Santa Barbara, an M.E. in Biomedical Engineering from University of Virginia and an MBA from Case Western Reserve University.
Andrew ElBardissi MD
As a Principal of the Private Transactions team, Dr. ElBardissi joined Deerfield in 2017 to work on structured transactions in Deerfield’s Private Design Funds. Prior to joining Deerfield, Dr. ElBardissi was a Principal at Longitude Capital where he focused on investments in medtech and biotechnology. Prior to Longitude, Dr. ElBardissi was an Associate in J.P. Morgan’s Healthcare Investment Banking practice.
His residency training in General Surgery was at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and has presented his research at numerous medical and surgical conferences. He holds an MD from the Mayo Clinic, an MPH in Quantitative Methods from Harvard University, an MBA from Harvard Business School and a BS with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.
Gregory Fiore MD
Dr. Fiore is a Co-Founder and is the Chief Medical Officer of Sollis Therapeutics. He is an entrepreneur and founder of two successful healthcare consulting firms, Fiore Healthcare Advisors and SSI Strategy. He was formerly the Chief Medical Officer of The Medicines Company, a global biopharmaceutical company. Dr. Fiore previously worked as a Strategy Consultant at McKinsey & Company and has held executive roles in several pharmaceutical / biotechnology companies such as Merck and Abbott Laboratories.
Dr. Fiore received Internal Medicine training at Harvard Medical School’s Brigham and Women’s Hospital and Pulmonary / Critical Care training in the Harvard Medical School Pulmonary and Critical Care Fellowship Program. He received his MD degree and was valedictorian at New York Medical College and received a B.S. degree in Zoology from the University of Rhode Island with honors.
Dr. Fiore serves on several medical and business advisory committees. He is on the Executive Board of the Institute of Neuromodulation (ION), the Scientific Advisory Board for Advera Health Analytics, the Business Advisory Board for Advanced Clinical Group, the Editorial Advisory Board of Clinical Leader, and the Executive Committee for the Safety of Oral Anticoagulants (SOAR) Registry. He has previously served on the Board of Dubset Media Holdings.
Steven Hochberg MBA
As a Partner on the Private Transactions team, Steve joined Deerfield in 2013 to work on structured transactions in Deerfield’s Private Design Funds. Steve has been a founder and manager of healthcare companies for more than 20 years.
Since 2004, Steve has managed Ascent Biomedical Ventures, a leading venture capital firm he co-founded focused on early stage investment and development of biomedical companies.
Since 2011, Steve has been the Chairman of the Board of Continuum Health Partners until its merger with Mount Sinai in 2013, where he is the Senior Vice Chairman of the Mount Sinai Health System, a $5 billion non-profit healthcare integrated delivery system in New York City. He graduated from the University of Michigan and earned his MBA from Harvard Business School.
Gregory Licholai MD MBA
Greg Licholai, MD is on the faculty at Yale University School of Management, co-director of the Yale Center for Digital Health, and is the Chief Medical Information Officer at PRA Health Sciences, a global drug development service firm. Previously, he was President and Chief Medical Officer at Castle Creek Pharmaceuticals and was responsible for all R&D activities. He is the founder and first President of Elpidera, a company focused on rare genetic and metabolic diseases, and was an executive at Amicus Therapeutics. He was director of Ventures and Business Development at Medtronic Neurological, where he was responsible for approval of a novel implantable device to treat pediatric dystonia.
He trained in neurosurgery at the Brigham and Women’s, Boston Children’s, and Massachusetts General Hospitals, was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health, performed research in molecular genetics at Yale and worked in molecular oncology at Rockefeller University. He received a B.S. from Boston College, Pre-Medical studies at Columbia University, an M.D. from Yale Medical School and an MBA from Harvard Business School. He is on the advisory boards of the National Tay Sachs and Allied Disease Foundation and the Partnership for Palliative Care, Yale Healthcare Conference and Yale Center for Biomedical Innovation and Technology and a lecturer at the Harvard Innovation Lab as well as Yale School of Management.
Steve Weinstein MBA
Steve Weinstein brings over 20 years of experience as a venture capitalist, CEO, and entrepreneur in biotech and medical device innovation.
As Managing Director of the Novartis Venture Fund for twelve years, he was actively engaged in all investment decisions across the global portfolio, managed the medical device practice, and invested in biotech. Prior to Novartis, Steve was on the life science team at Prism Venture Partners, where he focused on medical devices, and began his venture career as a Kauffman Fellow with Mid-Atlantic Venture Funds, focusing on software startups.
Steve has been a CEO of a venture-funded device company developing a therapy for hypertension, and a CEO of an industrial distribution business he bought out of bankruptcy and built profitably over five years.
Steve holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University.